<DOC>
	<DOC>NCT00352950</DOC>
	<brief_summary>To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC</brief_summary>
	<brief_title>Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically or cytologicallyconfirmed diagnosis of stage IIIB or IV NonSmall Cell Lung Cancer Received only one prior treatment (not including radiation) Measurable disease per Response Evaluation Criteria in Solid Tumors Group (RECIST) guidelines Life expectancy of ≥ 4 months Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate hematologic, renal and hepatic function Serumfasting cholesterol ≤ 300 mg/dL Serumfasting triglycerides ≤ 2.5 X ULN Brain metastases requiring treatment History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline Systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment Prior epidermal growth factor receptor targeting agents with the exception of the small molecule EGFr tyrosine kinase inhibitors Prior antitumor therapies including prior experimental agents or approved antitumor small molecules and biologics of short serum halflife (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum halflife within 6 weeks before enrollment Prior therapy with sirolimus, sirolimus analogs Immunosuppressive agents within 28 days before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>NSCLC, Lung cancer</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>mTOR</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>